Confo Therapeutics of Belgium entered into a research collaboration with AbCellera Biologics (NASDAQ:ABCL) for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets (G protein-coupled receptors).
GPCRs regulate a broad range of cellular processes that are critical for cancer: cellular proliferation, chemo-resistance, self-renewal, apoptosis, stress signaling, immune evasion, invasion, angiogenesis and metastasis.
Confo will apply its ConfoBody technology to stabilize the selected GPCRs in their disease-relevant conformations, which will then be used as antigens to enable antibody discovery and development.
Confo will be entitled to upfront payments, milestones, and tiered royalties on net product sales.
In a statement, Cedric Ververken, CEO of Confo, said the collaboration would serve as an additional validation recognizing the power of Confo’s platform and the ability to overcome the limitations of GPCR antibody discovery.
